DDInter1491 DDInter610
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.[L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy.[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may lead to a major life threatening interaction when taken with {v} Durvalumab
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Denosumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Pomalidomide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Pomalidomide {u} (Compound) causes {v} (Side Effect) Muscular weakness
Muscular weakness {u} (Side Effect) is caused by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Pomalidomide {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Upper respiratory tract infection {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} may lead to a major life threatening interaction when taken with {v} Durvalumab
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Pomalidomide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lenalidomide
Lenalidomide {u} may lead to a major life threatening interaction when taken with {v} Durvalumab
Pomalidomide {u} (Compound) resembles {v} (Compound) Thalidomide
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Pomalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Durvalumab
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may lead to a major life threatening interaction when taken with Durvalumab
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Pomalidomide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Pomalidomide (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Pomalidomide (Compound) causes Upper respiratory tract infection (Side Effect) and Upper respiratory tract infection (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide may lead to a major life threatening interaction when taken with Durvalumab
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Pomalidomide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lenalidomide (Compound) and Lenalidomide may lead to a major life threatening interaction when taken with Durvalumab
Pomalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Pomalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab